Short answer
GYRE THERAPEUTICS, INC. (GYRE) filed its Q2 2026 10-Q quarterly report on Aug 7, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $31M (up 15.9% year over year) with net income of −$23M.
Q2 2026 key financials · XBRL
- Revenue
- $31M
- +15.9% YoY · +37.7% QoQ
- Net income
- −$23M
- −1565.0% YoY · −132.7% QoQ
- Operating margin
- -77.3%
- EPS (diluted)
- −$0.16
- −1700.0% YoY · −60.0% QoQ
Source: XBRL data from the GYRE THERAPEUTICS, INC. (GYRE) Q2 2026 10-Q on SEC EDGAR. USD.
GYRE THERAPEUTICS, INC. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue $29.105M, down 2% YoY from $29.734M
- Net loss $14.270M vs $2.237M; operating loss $14.363M vs $2.240M
- Best segment: no segment revenue breakdown disclosed
- Cash $43.3M vs $49.2M at December 31, 2025; Cullgen acquired for approximately $300M in stock
- Near-term priorities: pipeline review, capital allocation, and program prioritization following Cullgen acquisition
Risk Factors
- New risk: pledged GNI Parties shares securing JPY 20 billion loan, triggered by GNI Japan financing Ayumi Pharmaceutical acquisition
- Most material update: foreclosure risk following loan maturity on July 1, 2027 and potential default
- Market risk: thin trading and concentrated ownership could amplify price declines from substantial share sales
- Governance risk: foreclosure could change control and end controlled-company status under Nasdaq rules
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other GYRE THERAPEUTICS, INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.